Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $310
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $275 to $310.
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $275 to $310.